SUNNYVALE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Prodeon Medical, Inc., a medical device company developing a minimally invasive treatment for lower urinary tract symptoms (LUTS) attributed to ...

50% of men over the age of 50 and up to 80% of all men overall, will eventually develop BPH with LUTS, representing about 40 million men in the United States who suffer from BPH 1,2,3. “We are excited ...

Company’s prospective, multi-center 240-patient, pivotal randomized controlled trial (RCT) earns AUA “Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s)” designation at conference’s ...

SUNNYVALE, Calif., March 16, 2026 (GLOBE NEWSWIRE)-- Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, announced it has received US FDA 510(k) clearance for the Urocross ...

The Urocross® Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind.

The MarketWatch News Department was not involved in the creation of this content. SUNNYVALE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Prodeon Medical, a privately held medical device company focused ...